

Maria Kataki, MD, PhD

Curriculum Vitae

Updated 7/6/17

ADDRESS:

Ohio State University
Wexner Medical Center
Department of Neurology
Memory and Cognitive Disorders Center
395 W 12th Avenue
6th floor, R 618
Columbus, Ohio 43210
Tel: (614) 293 4969
Email: maria.kataki@osumc.edu

BIOGRAPHICAL

Date of Birth: April 24, 1965.
Place of Birth: Chania, Crete, Greece.
Citizenship: Dual Citizenship: American, Greek

ACADEMIC APPOINTMENT

2004-2009:

Assistant Professor of Neurology, Neurobehavior Division, The Ohio State University, Columbus OH, USA.

2009 – current:

Assistant Professor Clinical, Memory and Cognitive Disorders Center, Wexner Department of Neurology, The Ohio State University, Columbus OH, USA.

2006 - 2012:

Cluster leader for the Independent Study Program, CNS Pathophysiology Module leader, The Ohio State University, College of Medicine, Columbus OH.

Affiliations

2004- 2011:

Consultant Regency Manor Nursing Home, Consulting Neurologist, Columbus, OH, USA.

EDUCATION & DEGREE

1983-1989:

Medical School of Athens, National and Kapodistrian University of Athens, Greece (MD)

1995-2003

National and Kapodistrian University of Athens, Greece, Department of Neurology. Dissertation title: “Contributions of SPECT in the early diagnosis of Alzheimer’s disease.” (PhD)

POST MD TRAINING:

1989-1991:

Rural area mandatory service, Health Center of Kissamos, Crete, Greece.

1991

Intern Department of Internal Medicine, Mental Diseases Hospital, Chania, Crete, Greece (6 months)

1992

Intern Department of Psychiatry, Mental Diseases Hospital, Chania, Crete, Greece (6 months).

1992-1995:

Resident in Neurology, National and Kapodistrian University of Athens, Eginition Hospital, Athens, Greece.

1993-1994:

Visiting Resident, Department of Neurology, Alzheimer's Disease Research Center, Baylor College of Medicine, Houston Texas (6 months).

1997:

Research Associate, Functional Neurosurgery, University of Texas, Health Science Center, Houston, Department of Neurosurgery, USA.

1998-1999:

Fellow in Alzheimer's Disease and Dementia Baylor College of Medicine, Department of Neurology and the Alzheimer's Disease Research Center, Houston TX, USA. (18 months)

1999-2000:

Intern, University of Texas-Houston Medical School, Houston TX, USA.

2000-2003:

Resident in Neurology, Baylor College of Medicine, Houston TX, USA.

2003:

Fellow in Alzheimer's Disease and Dementia. Baylor College of Medicine, Department of Neurology and the Alzheimer's Disease Center, Houston TX, USA. (6 months)

2004:

Fellow in Neurobehavioral Neurology: Section of Neurobehavioral Neurology and the Houston VAMC Cognitive Disorders Center, Houston TX, USA: (Three months)

BOARD EXAMS

- **1996 State Board Examination in Neurology, Greece, February**
- **1997 USMLE English Test**
- **1997 USMLE, STEP 1**
- **1997 USMLE, STEP 2**
- **2003 USMLE, STEP 3**
- **2003 ABPN, Part I**
- **2005 ABPN, Part II**
- **2005 Diplomate of the American Board of Psychiatry and Neurology, Inc., certificate #53386**
- **2011-present GCP for Investigational Site Staff Version 1.2 Course Code: 9902A-GCPR-Investigator-WBTO1-3410.**
- **2011 CITI Collaborative Institutional Training Initiative refresh course.**
- **2015 Diplomate of the American Board of Psychiatry and Neurology, Inc., re-certification (2/9/15).**

LICENSURE

- **1989 Medical Licensure (unrestricted in Greece).**
- **2003 Ohio State Medical Licensure, number 35083630.**

SOCIETIES

- **Diplomate of the American Board of Psychiatry and Neurology, Inc**
- **Member of the Board of the American Board of Medical Specialties**
- **American Academy of Neurology**
- **American Academy of Neurology, Neurobehavioral Section, volunteer member**
- **American Academy of Neurology, Geriatric Neurology Section, volunteer member**
- **International Alzheimer's Association**
- **Medical Association of Athens, Greece.**
- **Greek Neurological Association.**

AWARDS

- **Visiting Resident, Department of Neurology, Alzheimer's Disease Research Center, Baylor College of Medicine, Houston Texas , November 1993 - May 1994, sponsored by National university of Athens, Department of Neurology**
- **Travel Award, 6th International Conference on Alzheimer's Disease and Related Disorders. Amsterdam Rai 18-23 July 1998.**
- **Loren Rolak Award for 2003 for Best Online Case Publication in Neurology, Baylor College of Medicine, Department of Neurology**
- **Who's Who National Registry, 2004-2005**

- **Who's Who Madison Honorary Registry for Executive and Professionals, 2009-2011**
- **Who's Who Madison Honorary Registry for VIP Executive and Professionals 2009-2011**
- **International Association of Health Care Professionals. "The leading Physicians of the World". Publication 2012-2013-2014.**
- **Recipient of the Neurosciences Excellence Award 2012, OSU Wexner Medical Center, Department of Neurology.**
- **AAN Board of Directors, Seminar Director, 2016.**
- **America's Best Physicians, Directory 2016.**
- **America's Best Physicians, Directory 2017.**

SUPERVISING RESEARCH MENTORSHIP

- **Tarangi Sutaria: Undergraduate honor student in biomedical sciences research mentorship 2006-2007, 2007-2008, 2008-2009.**
"Evaluation of clinical parameters in patients participating in the Buckeye Brain Bank".
- **AFAR-OA student Alex Larson: Mentorship of a research project successfully completed: "A survival analysis of Alzheimer's disease patients treated with antientia medications". Data from The Buckey Brain Bank" Summer 2005**
- **AFAR-OA student Kay Ritsie: Research Mentorship: Identification of clinical phenotypes on the patients with Alzheimer's disease and correlation with APOE genotype analysis in brain tissue, Buckey Brain Bank data, successfully completed, summer 2006.**
- **Research mentorship: Bethany Solack, psychology student, The Ohio University: clinical parameters of patients underwent Brain Pet as part of the evaluation of a dementia syndrome. Summer 2007**
- **Clinical Preceptorship: Edward Chang MS 3 of the MD/PhD program, 7/07-12/07**

CLINICAL DUTIES

Memory Disorders Clinic: Six half clinic days a week at the Memory Disorders Clinic at the Ohio State University to evaluate new patients and follow up patients with Alzheimer's Disease or other types of Dementias, Cognitive Deficits associated with psychiatric conditions, Normal pressure hydrocephalus, metastatic disease of the brain, infections and inflammatory conditions of the brain, vasculitis of the central nervous systems, Cognitive

Deficits associated with adult manifestations of Mental Retardation and Attention Deficit Disorder at the Memory Disorders Clinic, The Ohio State University, serving approximately 30+patients a week during the past year. In the past I served seven half clinic days at the Memory Disorders Clinic and the Department of Neurology for a number of years.

Resident's Outpatient General Neurology Clinic 2004-2015. During my clinical duties in the resident's clinic I supervised and I taught the neurology residents during the outpatient clinics to evaluate patients with the whole spectrum of neurological disorders.

Inpatient Ward Service and Inpatient Consult Service where I supervise and I teach the neurology resident's and students to evaluate patients with neurological conditions. I also served as consultant in a nursing home for patients with cognitive and behavioral disturbances for a number of years (2004-2011).

Telemedicine prison clinic: I served as Neurology Attending Physician for the telemedicine prison clinic-general neurology resident's clinic for a number of years.

UNIVERSITY COMMITEES AND NATIONAL SERVICE

- 1. Compliance Committee: Department of Neurology, member, 2005-2006**
- 2. Neurology-Psychiatry case conferences committee, member, 2006-present**
- 3. Buckey Brain Bank brain autopsy program committee, member, 2005-present**
- 4. Medical student admission committee, appointed member, College of Medicine: 2006-2008**
- 5. Undergraduate honor student in biomedical sciences research mentorship 2006-present**
- 6. Cluster Leader for the Neuroscience committee, Independent Study Program, The Ohio State University, College of Medicine, appointed member, 2006-2012.**
- 7. CNS Pathophysiology Module Leader, The Ohio State University, College of Medicine, appointed member, 2006-present.**
- 8. LSI leader in neurological disorders, week 6 The Ohio State University, College of Medicine, 2012-2013.**

9. **LSI cortical syndromes articulate module leader, week 7. The Ohio State University College of Medicine, February 2013, February 2014.**
10. **Neuroscience Clinical Quality Management Committee, The Ohio State University Medical Center, appointed member, 2007-2012.**
11. **Institutional Review Board committee member, appointed member, The Ohio State University, appointed member, 2009-2015.**
12. **Education Committee member: 2010-present. The Ohio State University, Department of Neurology.**
13. **American Academy of Neurology, Neurobehavioral Section, volunteer member, 2011-present.**
14. **American Academy of Neurology, Geriatric Neurology Section, volunteer member, 2011-present.**
15. **Academic Standing Committee (ASC), Appointed member, Ohio State University, College of Medicine. 11-1-14 through present.**
16. **Director of Seminar “Management of Behavioral Disturbances in Dementia”. AAN Annual Meeting Vancouver, CA, 2016.**

INVITED SPEAKER

- **Grand Round Talk, 12/4/02, University of Alabama at Birmingham: Alzheimer’s disease, Overview.**
- **Grand Round Talk, 2/19/03, Ohio State University at Columbus: Alzheimer’s Disease, Past, Present, Future.**
- **Grand Round Talk, 4/16/03, University of Texas, Medical Branch at Galveston: Alzheimer’s Disease, an update.**
- **16th Annual Geriatric Medicine Conference, Salt Fork Park Lodge, Ohio, Oct 22-24, 2004: Behavioral Management of Dementia.**
- **Alzheimer’s Disease: An update in management” Department of Internal medicine, Residency Lecture. 8/2/05.**

- **Invited Discussant: OSU Department of Psychiatry, Grand Rounds "Behavior Problems in Dementia, presented by Dr. Stephen Pariser, 12/05.**
- **Division of Quality Assurance. Ohio Department of Health. Dementia Conference 4/3/06. "Mild Cognitive Impairment".**
- **Webcast - OSU MedNet 21: "Mild Cognitive Impairment". 11/2/07.**
- **Grand Round Talk, "Prion Diseases". Southern Illinois School of Medicine, Department of Neurology. 6/10/08.**
- **Webcast - OSU MedNet 21: "An overview of Dementia". 9/19/08.**
- **Invited Speaker Combined Neurology/Neurosurgery Grand Rounds, OSU, "Normal Pressure Hydrocephalus, An Overview". 12/11/11.**
- **Webcast - OSU MedNet 21: New approach to memory loss. 10/19/12.**
- **NeuroPI: Falls Refresh module. Donald J. Iverson, MD, FAAN, NeuroPI Editor
Author: Maria Kataki MD, PhD, Germaine Odenheimer, MD, FAAN. American Board of Psychiatry and Neurology Core Competencies 9/2015 (active module for three years).**
- **Expert reviewer of the American Academy of Neurology (AAN) guideline protocol, "Pharmacologic Treatment of Migraine Headache in Children". 6/2015**
- **Management of Behavioral Disturbances in Dementia. AAN Breakfast Seminar Director-Introduction. AAN 4/20/16.**
- **Management of Agitation and Psychosis in Dementia. Presentation AAN Breakfast Seminar Management of Behavioral Disturbances in Dementia. AAN 4/20/16.**

PRESENTATIONS

1. **"Etiology of Alcoholism," Medical School of Athens, Seminar Series, November 1987.**
2. **"Causes, Symptoms, and Preventive Measures against AIDS," Educational Program on Preventive Medicine sponsored by the Ministry of Health of Greece, December 1989.**
3. **"Bacterial Meningitis," Hospital Grand Rounds, Department of Internal Medicine, Mental Disease Hospital of Chania, December 1991.**
4. **"Hemichorea-Hemiballismus," Hospital Grand Rounds, Department of Neurology, Eginition Hospital, May 1993.**

5. "Arteriovenous Malformations of the Spinal Cord," Hospital Grand Rounds, Eginition Hospital, Athens, Greece, October 1994.
6. "Neuropsychological, neurophysiological, neuroimaging and brain blood flow study with SPECT in Demented and Epileptic patients".A. Kolintou, N. Sifakis, P. Kostamis, *M. Katakis*, S.Gatzonis, M. Spanaki, I. Zalonis, P. Sgouropoulos, C. Papageorgiou. Semiannual meeting of the Greek Neurological Association, 1994.
7. "Antiphospholipid Antibodies Syndrome, Neurological Complications. Presentation of four cases." T. Zambelis, *M. Katakis*, C. Boumbourakis, E. Andreadou, L. Besmertis, C. Papageorgiou 14th Annual Conference of Greek Neurological Association, Athens, Greece, November 1995.
8. "Event Related Potentials in Patients with Dementia." N. Triantafidou, *M. Katakis*, K. Papageorgiou, 14th Annual Conference of Greek Neurological Association, Athens, Greece, November 1995.
9. "SPECT study in Alzheimer's disease and correlations with disease severity and cognitive performance." *M.Katakis*, N. Sifakis, A. Kolintou, I. Zalonis, P. Sgouropoulos, P. Kostamis, C. Papageorgiou. 14th Annual Conference of Greek Neurological Association, Athens, Greece, November 1995.
10. "Semiquantitative analysis of SPECT with ROIs in Alzheimer's disease patients." N. Sifakis, *M. Katakis*, P. Sgouropoulos, P. Kostamis, A. Kolintou, C. Papageorgiou., Fifth Greek Annual Conference on Nuclear Medicine, Patra, Greece, March 1996.
11. "Contributions of SPECT in the assessment of Alzheimer's disease." *M. Katakis*, P. Gourtzelidis, N. Sifakis, A. Kolintou, I. Zalonis, P. Sgouropoulos, P. Kostamis, and C. Papageorgiou. Fifteenth Annual Conference on Biomedical Engineering Research in Houston, 1997.
12. "SPECT study in Dementia." *M. Katakis*, P. Gourtzelidis, N. Sifakis, A. Kolintou, I. Zalonis, P. Sgouropoulos, S. Perisinaki, P. Kostamis, and C. Papageorgiou. Twenty Third Annual Hellenic Conference on Medicine. Athens, 1997.
13. "Stereotactic Radiosurgery of Angiographically Occult Vascular Malformations". *M. Katakis*, N. Hashimoto, O. Zeck, W. Gormley. Sixteen Annual Conference on Biomedical Engineering Research in Houston, 1997.
14. "The Presence of APOε4 does not Influence Rate of Decline in Alzheimer's Disease". *M. Katakis*, R.S. Doody, J. Y. Liao, J. Sims. 6th International Conference on Alzheimer's Disease and Related Disorders. Amsterdam Rai 18-23 July 1998.
15. "Primary Degenerative Dementias": Resident Lecture Series, Baylor College of Medicine, Department of Neurology, 2001.

16. **“Gene Therapy for Gliomas”**: *M. Katakai*, Basic Science Seminar, Baylor College of Medicine, Department of Neurology, 2001.
17. **“Iron and Neurodegeneration”**: *M. Katakai*, Basic Science Seminar, Baylor College of Medicine, Department of Neurology, 2003.
18. **“Primary Degenerative Dementias”**: PA Lecture Series, Baylor College of Medicine, Department of Neurology, April 2003.
19. **“Alzheimer’s Disease: Past-Present-Future”**. Grand Rounds, Baylor College of Medicine, Department of Neurology, June 2003.
20. **“SPECT findings in Alzheimer’s Disease and correlation with disease severity”** poster presentation in the 9th International Conference on Alzheimer’s Disease and Related Disorders, Philadelphia, Pennsylvania, USA, July 17-22, 2004.
21. **“Primary Degenerative Dementias: Resident Lecture**, OSU Department of Neurology, November 2004.
22. **“APOE and Alzheimer’s disease”** A 10 year update. OSU Department of Neurology, Grand Rounds 2/25/05.
23. **“Behavioral Neurology”**. Resident Lecture. OSU Department of Neurology, March 22, 2005.
24. **Alzheimer’s Disease: An update in management”** Department of Internal medicine, Residency Lecture. 8/2/05.
25. **Alzheimer’s Disease: Understanding current management**. OSU Department of Neurology, Grand Rounds 11/29/05.
26. **“Dementia”**. M3 Neuroscience clerkship. OSU Department of Neurology, 3/15/06.
27. **“The Buckeye Brain Bank”** OSU Neurology Grand Rounds. 1/23/07
28. **“The non Alzheimer’s Dementias”** OSU Department of Neurology, resident lecture series, 8/30/06.
29. **“Dementia”**. M3 Neuroscience clerkship. OSU Department of Neurology, 5/9/07.
30. **Webcast - OSU MedNet 21: “Mild Cognitive Impairment”**. 11/ 2/07.
31. **“Mild Cognitive Impairment: OSU Department of Neurology, Grand Rounds**, 11/6/07.
32. **“Creutzfeldt-Jacob”** disease: OSU Department of Neurology, resident lecture, 11/28/07.

33. "Dementia". M3 Neuroscience clerkship. OSU Department of Neurology, 2/15/08.
34. "Dementia". M3 Neuroscience clerkship. OSU Department of Neurology, 4/12/08.
35. "Prion Diseases". Grand Rounds SIU Neurology. 6/10/08.
36. "Dementia". M3 Neuroscience clerkship. OSU Department of Neurology, 6/25/08.
37. Webcast - OSU MedNet 21: "An overview of Dementia". 9/19/08.
38. "An overview of Dementia" OSU Department of Neurology, resident lecture, 10/01/08.
39. "Dementia". M3 Neuroscience clerkship. OSU Department of Neurology, 10/15/08.
40. Grand Round Talk, "Prion Diseases". OSU Neurology. 1/6/09.
41. "Dementia". M3 Neuroscience clerkship. OSU Department of Neurology, 2/25/09.
42. "Dementia". M3 Neuroscience clerkship. OSU Department of Neurology, 4/22/09.
43. "Dementia". M3 Neuroscience clerkship. OSU Department of Neurology, 6/24/09.
44. "Prion Diseases" OSU Neurology, Resident's Lecture, 10/28/09.
45. "Dementia". M3 Neuroscience clerkship. OSU Department of Neurology, 2/24/10.
46. "Dementia, overview". M3 Neuroscience clerkship. OSU Department of Neurology, 4/21/10.
47. Small Group M1 Assorted cases, 5/6/10.
48. Small Group M1 Assorted cases, 5/18/10.
49. "Dementia, overview". M3 Neuroscience clerkship. OSU Department of Neurology, 6/23/10.
50. "Alzheimer' Disease" Resident's Lecture, Department of Neurology, 10/15/10,.
51. "Lewy Body Dementia" Resident's Lecture, Department of Neurology, 10/22/10.
52. "Dementia" M3 Neuroscience clerkship. OSU Department of Neurology, 10/27/10.
53. "Dementia" M3 Neuroscience clerkship. OSU Department of Neurology, 12/1/10.
54. "Dementia" M3 Neuroscience clerkship. OSU Department of Neurology, 2/23/11.
55. "Dementia" M3 Neuroscience clerkship. OSU Department of Neurology, 4/20/11.

56. Small Group M1 Assorted cases, 5/4/11.
57. "Dementia" M3 Neuroscience clerkship. OSU Department of Neurology, 6/9/11.
58. "Dementia" M3 Neuroscience clerkship. OSU Department of Neurology, 10/19/11.
59. "Prion diseases" Resident's Lecture, OSU Department of Neurology, 11/21/11.
60. Invited Speaker Combined Neurology/Neurosurgery Grand Rounds, OSU, "Normal Pressure Hydrocephalus, An Overview". 12/1/11.
61. "Dementia" M3 Neuroscience clerkship. OSU Department of Neurology, 12/14/11.
62. "Dementia" M3 Neuroscience clerkship. OSU Department of Neurology, 2/21/12.
63. "Differences in the Cognitive Profiles of Parkinsonian Dementia Syndromes and Alzheimer's Disease". Scharre DW, Chang SI, *Kataki M*, Agrawal P, Park A, Kostyk S, Davis R, Kovesci R, Nagaraja HN. Poster presentation ID# 967. American Medical Directors Association Long Term Care Medicine meeting in San Antonio, March 2012. Abstract posted in JAMDA.
64. "Dementia" M3 Neuroscience clerkship. OSU Department of Neurology, 5/2/12.
65. Small Group M1 Neuroscience course assorted cases, 5/10/12.
66. "Dementia" M3 Neuroscience clerkship. OSU Department of Neurology, 6/13/12.
67. "Memory Profiles Differ between Parkinsonian Dementia Syndromes and Alzheimer's Disease". Scharre DW, Chang SI, *Kataki M*, Agrawal P, Park A, Kostyk S, Nagaraja HN. Poster presentation ID#30765 Alzheimer's Association International Conference (AAIC) 2012 Vancouver, British Columbia, Canada, July 14-19, 2012.
68. "Dementia" M3 Neuroscience clerkship. OSU Department of Neurology, 8/22/12.
69. "Alzheimer's Disease an update". Resident's lecture series. OSU Department of Neurology 10/10/12.
70. "Dementia" M3 Neuroscience clerkship. OSU Department of Neurology, 10/10/12.
71. Webcast - OSU MedNet 21: New approach to memory loss. 10/ 19/12.
72. "Subcortical Dementias". Resident's Lecture series. OSU Department of Neurology 10/24/12.
73. "Parkinsonian Dementias". Resident's Lecture series. OSU Department of Neurology 10/29/12.

74. “Dementia, an update” M3 Neuroscience clerkship. OSU Department of Neurology, 2/20/13.
75. “The Cortical Syndromes” M1 Articulate module presentation, 2/25/13. The Ohio State University, College of Medicine.
a. <http://vitals.osumc.edu/articulate/2559/player.html>
76. “Distinguishing Parkinsonian Dementia Syndromes from Alzheimer’s Disease: Behavioral and Cognitive Characteristics Using SAGE” poster presentation at the American Academy of Neurology 65th Annual Meeting, March 16 to March 23, 2013 at the San Diego Convention Center, San Diego, CA. Scharre WD, Chang SI, Nagaraja HN, Agrawal P, *Kataki M*, Linder S, Park A.
a. #P07.134 Poster Session P07, 3/21/2013.
77. “Dementia, an update” M3 Neuroscience clerkship. OSU Department of Neurology, 5/1/13.
78. “Dementia, an update” M3 Neuroscience clerkship. OSU Department of Neurology, 5/15/13.
79. “Dementia, an update” M3 Neuroscience clerkship. OSU Department of Neurology, 8/21/13.
80. “Prion Diseases”: Resident’s Lecture, OSU Department of Neurology, 10/30/13.
81. “Multiplexed RNA amplicon sequencing reveals altered gene expression and functional regulatory variants in dementia with Lewy bodies.”: Poster #430, 11/11/13 San Diego, CA Neuroscience 2013. Control/Tracking Number: 2013-S-12302-SfN.: *R. Maschrenchas R., M. Smith, A. C. Papp, D. W. Scharre, M. Kataki, W. Sadee.
82. “Dementia, an update” M3 Neuroscience clerkship. OSU Department of Neurology, 12/11/13.
83. “The Other Cortical Syndromes”, articulate course in LSI curriculum. The Ohio State University, module in neurological disorders, 2/25/14 College of Medicine.
84. “Dementia, an update” M3 Neuroscience clerkship. OSU Department of Neurology, 4/2/14.
85. “Paired Comparison Study Distinguishing Parkinsonian Dementia Syndromes from Parkinson’s Disease”. Poster presentation #2360 American Academy of Neurology 66th Annual Meeting 4/30/2014: Douglas Scharre, Shu-Ing Chang; Haikady Nagaraja; Ariane Park; Punit Agrawal, Anahita Adeli, Shannon Linder; Anne Kloos, Deborah Kegelmeyer, Nora Fritz, *Maria Kataki*.
86. “Motor and Cognitive Profiles Differ between Lewy Body Dementia and Parkinson’s Disease in a Paired Comparison Study”. Poster presentation #44166. ICAD. Douglas

W. Scharre, Shu-Ing Chang; Haikady Nagaraja; Ariane Park; Punit Agrawal, Anahita Adeli, Shannon Linder; Anne Kloos, Deborah Kegelmeyer, Nora Fritz, Maria Katak, Sandra Kostyk. 7/15/14 Copenhagen, Denmark.

- 87. “Dementia, an update” M3 Neuroscience clerkship. OSU Department of Neurology, 5/7/14.**
- 88. “Comparison of gait and mobility measures in Dementia with Lewy Bodies, Parkinson’s Disease with Dementia, Alzheimer’s Disease, and Parkinson’s Disease”. DA Kegelmeyer, AD Kloos, NE Fritz , SI Chang, A Park , P Agrawal, A Adeli , S Linder , *M Katak* , DW Scharre , SK Kostyk. Parkinson's Study Group meeting in September 2014 in St. Louis. Abstract published in the journal Movement Disorders.**
- 89. “Longitudinal Changes in Self-Administered Gerocognitive Examination (SAGE) Scores for Subjective Cognitive Impairment (SCI), Mild Cognitive Impairment (MCI), Dementia Converters, and Alzheimer’s Disease (AD) Patients”. Poster Presentation P4.088 AAN 67th meeting 4/22/2015. Douglas Scharre, Shu-Ing Chang, Haikady Nagaraja, *Maria Katak*, Natalie Wheeler, Anahita Adeli.**
- 90. “Longitudinal Changes in Self-Administered Gerocognitive Examination (SAGE) and Mini-Mental State Examination (MMSE) Scores for Subjective Cognitive Impairment (SCI), Mild Cognitive Impairment (MCI), Dementia Converters, and Alzheimer’s Disease (AD) Patients”. Poster Presentation AAIC 7/20/15. Douglas Scharre, Shu-Ing Chang, Haikady Nagaraja, *Maria Katak*, Natalie Wheeler, Anahita Adeli.**
- 91. “Alzheimer’s Disease an update in diagnosis and management”. Resident’s lecture series. OSU Department of Neurology 4/8/15.**
- 92. “Lewy Body Dementia”. Resident’s lecture series OSU Department of Neurology 4/16/15.**
- 93. “Gene expression profiling of anterior cingulate cortex from subjects with Lewy body dementia”. Poster Presentation SFN annual meeting. October 19, 2015 M. Pietrza, A. Papp, A. Curtis, M. Katak, D. Scharre, G. Rempala, W. Sadee.**
- 94. “The Spectrum of Prion Diseases”. Resident’s lecture series. OSU Department of Neurology 10/22/15.**
- 95. Management of Behavioral Disturbances in Dementia. AAN Breakfast Seminar Director-Introduction. AAN 4/20/16.**
- 96. Management of Agitation and Psychosis in Dementia. Presentation AAN Breakfast Seminar Management of Behavioral Disturbances in Dementia. AAN 4/20/16**

97. **Digital Self Administered Examination eSAGE. Abstract ID a10039 in Alzheimer's and Dementia conference proceedings. AAIC July 28 2016, Toronto, CA. Oral presentation. D. Scharre, S Chang, H Nagaraja, N Vrettos, M Kataki.**
98. **"Alzheimer's Disease an update in diagnosis and management". Resident's lecture series. OSU Department of Neurology 5/10/17.**
99. **Digital Translated Self-Administered Gerocognitive Examination (eSAGE): Relationship to Clinical Assessments. AAIC July 16 2017, London, England. Poster presentation. Scharre DW, Chang S-I, Nagaraja HN, Vrettos N, Kataki M.**

CLINICAL RESEARCH AS CO OR SUB INVESTIGATOR (FUNDED)

1. **1999: Subinvestigator for Talsaclidine BL Trial No 506.203 efficacy and safety of 6, 12, 24 and 36mg tid po talsaclidine for 12 weeks in double blind randomized controlled parraled group comparison in patients with mild to moderate dementia of the Alzheimer's type.**
2. **1998-1999: Subinvestigator for Memantine efficacy and long term tolerability of Memantine in patients with moderately severe to severe Alzheimer's Disease MRZ 9001-9605 Trial phase III Syly 98-312000, multicenter randomized placebo controlled Double Blind, open label extension.**
3. **1999: Subinvestigator WHIMS study phase 3 Clinical Evaluation**
4. **1999: Subinvestigator MCI Donepezil and Vitamin E Phizer study. A randomized Double Blind Placebo Controlled Trial to evaluate the safety and efficacy of Vitamin E and Donepezil HCL to delay clinical progression from Mild Cognitive Impairment to Alzheimer's Disease.**
5. **1999: Subinvestigator Melatonin study: Multicenter placebo Controlled Trial of Melatonin for sleep disturbance in Alzheimer's disease**
6. **2003: Subinvestigator The Alzheimer's Disease Cooperative Study, Homocysteine study. A randomized Double Blind Placebo Controlled Trial to evaluate if lowering homocysteine levels will slow the rate of cognitive decline in Alzheimer's disease.**
7. **2003: Subinvestigator The Alzheimer's Disease Cooperative Study, Statin (Simvastatin) Study. A randomized Double Blind Placebo Controlled Trial to evaluate safety, tolerability and effectiveness of simvastatin to slow the progression of Alzheimer's disease**
8. **2003: Subinvestigator Lipitor Study. A study to evaluate safety and effectiveness of atrovastatin when taken with donepezil is useful for treating Alzheimer's disease.**

9. **2003-2004: Subinvestigator Xaliproden study. A randomized, multicenter, double-blind, placebo-controlled, 18 month study of the efficacy of Xaliproden in patients with mild to moderate dementia of the Alzheimer's type.**
10. **2003-2004: Subinvestigator Donepezil Hydrochloride in MCI. A One-Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects with Mild Cognitive Impairment.**
11. **2003: Subinvestigator Donepezil Hydrochloride in Severe Alzheimer's Disease. A 24 Week, Multicenter, Randomized, Double-blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Donepezil Hydrochloride (E2020) in Patients with Severe Alzheimer's Disease followed by a 12 week open-label extension period.**
12. **2004: Subinvestigator ONO-2506. A Double-Blind, Phase II, Safety and Efficacy evaluation of ONO-2506 in patients with mild to moderate Alzheimer's Disease**
13. **2004-2005: Subinvestigator A Randomized, Double-Blind, Placebo-Controlled Parallel Group Phase 2 Study to Evaluate the Safety and Efficacy of FK962 in Subjects with Mild to Moderate Alzheimer's disease.**
Sponsor: Astellas
14. **2004: Subinvestigator Rasagiline Mesylate. A 1 year, Double-Blind, randomized, placebo-controlled, study of Rasagiline 1mg and 2mg added to Aricept 10mg daily in patients with mild to moderate dementia of the Alzheimer's type.**
15. **2004-2005: Subinvestigator SRA-333/protocol 203. A 3 month, randomized, double-blind, placebo-controlled, multicenter, safety, tolerability, and efficacy study of 3 doses of SRA-333 in outpatients with mild to moderate Alzheimer's Disease with Donepezil as active control.**
16. **2004-2005: Subinvestigatory SRA-333/protocol 201 (serotonin inhibitor). A three month double blind, placebo controlled multicenter, safety, tolerability and efficacy study of SRA-333 in outpatients with mild to moderate Alzheimer's disease.**
17. **2004: Co Principal Investigator: Galantamine ER Open Label Rapid Dose Escalation Trial in Alzheimer's Disease.**
18. **2004-2005: *Principal Investigator*: A randomized, Double-Blind, Placebo-Controlled Evaluation of the Effectiveness and Safety of Memantine in Nursing Home Residents with Moderate to Severe Alzheimer's Disease (MEM-MD-22).**
Sponsor: Forest Research Institute
19. **2005: Subinvestigator MEM-MD-11: A Long-Term Study Evaluating the Safety and Tolerability of BID and QD Administration of Memantine in Patients with Mild to Moderate Dementia of the Alzheimer's Type.**
Study closed: 1/26/2006
Sponsor: Forest Research Institute

- 20. 2005: Subinvestigator NER-MD-03: An Evaluation of the Long-Term Safety and Efficacy of Neramexane in Patients with Moderate to Severe Dementia of the Alzheimer's Type.**
Sponsor: Forest Research Institute
- 21. 2005-2007: Subinvestigator EFC2724: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 18 Month Study of the Efficacy of Xaliproden in Patients with Mild-To-Moderate Dementia of the Alzheimer's Type**
Sponsor: Sanofi-Aventis
- 22. 2005-2007: Subinvestigator ONO-2506POU010: A Double-Blind, Phase II, Safety and Efficacy Evaluation of ONO-2506po in Patients with Mild to Moderate Alzheimer's Disease.**
Sponsor: ONO Pharma
- 23. 2005-2007: Subinvestigator MPC-7869-04-005: A phase 3 Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of the Effect of Daily Treatment with MPC-7869 on Measures of Cognitive and Global Function in Subjects with Mild to Moderate Dementia of the Alzheimer's Type.**
Sponsor: Myriad
- 24. 2005-2006: Subinvestigator E2020-A001-412: A One-Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects with Mild Cognitive Impairment**
Sponsor: Eisai/Pfizer
- 25. 2005-2007: Subinvestigator TVP-1012-A001-201: A 1-year, Double-Blind, Randomized, Placebo-Controlled, Study of Rasagiline 1 mg and 2 mg Added to Aricept 10 MG Daily in Patient with Mild to Moderate Dementia of the Alzheimer's Type.**
Sponsor: EISAI/TEVA
- 26. 2005: Subinvestigator NER-MD-02: A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Neramexane in Patients with Moderate to Severe Dementia of the Alzheimer's Type.**
Sponsor: Forest
- 27. 2005: 03-0-189 FK962: Subinvestigator. A Randomized, Double-Blind, Placebo-Controlled Paralled Group Phase 2 Study to Evaluate The Safety and Efficacy of FK962 in Subjects with Mild to Moderate Alzheimer's disease.**
- 28. 2005-2006: Subinvestigator. A Double – blind placebo-controlled study of VP 4896 for the treatment of mild to moderate Alzheimer's disease (Protocol number VP-AD-301). Sponsored by Voyager Pharmaceutical Corporation: an investigational drug trial.**

29. **2005-2007: A double-blind, randomized, placebo-controlled study of the efficacy, safety and tolerability of 8 week treatment of Rozerem 8mg (qhs) in sleep disturbed, community dwelling, mild to moderately severe Alzheimer's disease subjects (Protocol number Takeda 01-05-TL-375-061). Sponsored by Takeda: an investigational drug trial.**
30. **2004-present: Alzheimer's disease Neuroimaging Initiative (ADNI). Subinvestigator. Supported by the National Institute on Aging and private organizations.**
31. **2006-2008: Subinvestigator: A 54 week, double- blind, randomized, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone (extended release tablets) as adjunctive therapy to acetylcholinesterase inhibitors on cognition and overall clinical response in APOE e4-stratified subjects with mild to moderate Alzheimer's disease, AVA102670**
32. **2006-2007: Subinvestigator: A randomized Double-Blind Placebo-controlled trial of the effects of Docosaenoic acid (DHA) in slowing the progression of Alzheimer's Disease. Alzheimer's Disease Cooperative Study (ADCS).**
33. **2007-2008: E2020-G000-326: Subinvestigator: Double-Blind, Parallel-Group Comparison of 23 mg Donepezil Sustained Release to 10 mg Donepezil Immediate Release in Patients with Moderate to Severe Alzheimer's Disease. Sponsor: Eisai**
34. **2007-2010: Subinvestigator: Double-blind, parallel-group comparison of 23 mg donepezil sustained release to 10 mg donepezil immediate release in patients with moderate to severe Alzheimer's ailment (protocol number E2020-G000-327). Sponsored by Eisai,Inc.: an investigational drug trial; 2007-2010.**
35. **2008-2010: Subinvestigator Open-label extension of 23 mg donepezil sustained release in patients with moderate to severe Alzheimer's disease (protocol number E2020-G000-328). Sponsored by Eisai,Inc.: an investigational drug trial;**
36. **2007-2008: MPC-7869-05-009: Subinvestigator: An Open Label Study of the effect of Daily Treatment with MPC-7869 in Subjects with Dementia of the Alzheimer's Type. Sponsor: Myriad Pharmaceuticals**
37. **2007: Subinvestigator. Exelon Patch: A Prospective, Open-Label, Randomized, Multi-Center, Parallel-Group Study of 5 weeks, with a 20-Week Extension Evaluating the Tolerability and Safety of Switching from Donepezil to an Initial Dose of 5cm² Rivastigmine Patch. Sponsor: Novartis**
38. **2008-2009: Subinvestigator. AVA102675: A 52-week open-label extension study of the long-term safety and efficacy of Rosiglitazone extended release (RSG XR) as adjunctive therapy to acetylcholinesterase inhibitors in subjects with mild-to-moderate Alzheimer's disease (REFLECT-4). Glaxo Smith-Kline**

- 39. 2008- 2009: Subinvestigator. AX3110866: A Fixed-Dose study of SB-742457 versus placebo when added to existing Donepezil treatment in subjects with Alzheimer's disease. Glaxo Smith-Kline.**
- 40. 2008- 2010: Subinvestigator Effect of γ -Secretase Inhibition on the Progression of Alzheimer's disease: LY450139 versus Placebo. Eli-Lilly**
- 41. 2009-present: Subinvestigator: A double-blind placebo-controlled preliminary study of the efficacy, safety and tolerability of ST101 in the treatment of Alzheimer's disease in subjects concurrently receiving donepezil (Aricept). (protocol number ST101-A001-202). Sponsored by Sonexa Therapeutics, Inc.: an investigational drug trial.**
- 42. 2009-present: Subinvestigator An open label study of the safety and tolerability of ST101 in subjects with Alzheimer's disease (protocol number ST101-A001-401). Sponsored by Sonexa Therapeutics, Inc.: an investigational drug trial**
- 43. 2007-present: Subinvestigator: Multi-center trial to evaluate home-based assessment methods for Alzheimer's disease prevention research in people over 75 years old. Supported by the National Institute on Aging.**
- 44. 2008-2012: Subinvestigator: A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel group, efficacy and safety trial of bapineuzumab (AAB 001, ELN115727) in patients with mild to moderate Alzheimer's disease who are apolipoprotein E non-carriers (protocol number AAB-001-ELN115727-301). Sponsored by Elan Pharmaceuticals Inc.: an investigational drug trial.**
- 45. 2008-2012: Subinvestigator: A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel group, efficacy and safety trial of bapineuzumab (AAB 001, ELN115727) in patients with mild to moderate Alzheimer's disease who are apolipoprotein E carriers (protocol number AAB-001-ELN115727-302). Sponsored by Elan Pharmaceuticals Inc.: an investigational drug trial.**
- 46. 2009-2012: Subinvestigator: A phase III multicenter, parallel-group, long term safety and tolerability treatment trial of bapineuzumab (AAB 001, ELN115727) in subjects with Alzheimer's disease who participated in study ELN115727-301 or in study ELN115727-302 (protocol number AAB-001-ELN115727-351). Sponsored by Elan Pharmaceuticals Inc.: an investigational drug trial.**
- 47. 2009-2012: Subinvestigator: A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group efficacy and safety trial of bapineuzumab (AAB-001, ELN115727) in subjects with mild to moderate Alzheimer disease who are apolipoprotein E e4 carriers (protocol number 3133K1-3001-US). Sponsored by Wyeth: an investigational drug trial.**
- 48. 2010-2012: Subinvestigator: A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group efficacy and safety trial of bapineuzumab (AAB-**

001, ELN115727) in subjects with mild to moderate Alzheimer disease who are apolipoprotein E e4 non carriers (protocol number 3133K1-3000-US). Sponsored by Pfizer: an investigational drug trial.

- 49. 2009-2010: Subinvestigator: A multicenter, randomized double-blind placebo-controlled study of the safety, tolerability, pharmacodynamic and pharmacokinetic effects of BMS-708163 in the treatment of patients with mild to moderate Alzheimer's disease (protocol number CN156013). Sponsored by Bristol-Myers Squibb: an investigational drug trial.**
- 50. 2009-present: Subinvestigator: A multicenter, randomized double-blind placebo-controlled study of the safety, tolerability, pharmacodynamic and pharmacokinetic effects of BMS-708163 in the treatment of patients with prodromal Alzheimer's disease (protocol number CN156018). Sponsored by Bristol-Myers Squibb: an investigational drug trial.**
- 51. 2010: Sub investigator: Safety Evaluation of Florbetapir F 18 (18F-AV-45) (Avid Radiopharmaceuticals) in subjects participating in the Alzheimer's Disease Neuroimaging Protocol Grand Opportunity (ADNI-GO) Protocol # ADC-038 Protocol #18F-AV-45-A15-ADNI-GO. Alzheimer's Disease Neuroimaging Initiative 2 (ADNI-2) Protocol # ADC-039. Sponsor ADCS.**
- 52. 2010: Sub investigator: Phase 3 Extension, Multicenter, Long-Term Safety and Tolerability of Bapineuzumab (AAB-001, ELN115727) in Subjects With Alzheimer's Disease Who Are Apolipoprotein E e4 Carriers and Participated in Study 3133K1-3001-US. Sponsored by Wyeth.**
- 53. 2012: Sub investigator: Protocol CN167003: A Multi Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects with Mild Alzheimer's Disease.**
- 54. 2012: Sub Investigator: A Phase 3B prospective, observational, multicenter, post discontinuation follow up study of subjects with Alzheimer's Disease who discontinued treatment in Bapineuzumab phase 3 clinical studies. ELN115727-301, ELN115727-302, ELN115727-351 or failed to enroll.**
- 55. 2012: Sub Investigator: Cerebral fluid (CSF) and blood repository (Buckeye Biospecimen Repository) evaluating biomarkers for degenerative brain conditions. Phylogeny, Inc.**
- 56. 2012: Multicenter trial to evaluate home-based assessment methods for Alzheimer's Disease prevention research in people over 75 years old. UCSD ADC030.**
- 57. 2012: Subinvestigator: A phase III, Extension multicenter, Parallel-Group, Long-Term Safety and Tolerability, double-blind, trial of bapineuzumab (AAB-001,**

ELN115727) in subjects with Alzheimer disease who are apolipoprotein E e4 non carriers and participated in study 3133K1-3000-US). Sponsored by Wyeth.

- 58. 2012-present: Subinvestigator: A phase 2, randomized, double-dummy, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-923 (dextromethorphan/quinidine) for the treatment of symptoms of agitation in patients with Alzheimer's disease. AVANIR.**
- 59. 2012-2013: Subinvestigator: Pfizer 3003: A Phase 3 Extension, Multicenter, Long-term Safety and Tolerability Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects with Alzheimer Disease Who are Apolipoprotein E e4 Carriers and Participated in Study 3133K1-3001-US.**
- 60. 2014: Subinvestigator: Pfizer B2081011: A randomized, 18-week, placebo-controlled, double-blind, parallel group study of the safety and efficacy of PF-05212377 (SAM-760) in subjects with mild-to-moderate Alzheimer's disease with existing neuropsychiatric symptoms on a stable daily dose of Donepezil.**
- 61. 2013-present: Subinvestigator : BMS003, A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effects of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects with Mild Alzheimer's Disease.**
- 62. 2013-2014:Subinvestigator:A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of MK-7622 as an Adjunctive Therapy to Donepezil for symptomatic Treatment in Subjects with Alzheimer's Disease. Protocol MK-7622-012-00. Sponsored by Merck**
- 63. 2013-2014:Subinvestigator: An Efficacy and Safety Trial of MK-8931 (SCH 900931) in Subjects with Amnesic Mild Cognitive Impairment (aMCI) due to Alzheimer's Disease (Prodromal AD). Protocol 019-00. Sponsored by Merck**
- 64. 2013-2014:Subinvestigator: Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430P Versus Placebo. Protocol H8A-MC-LZAX Sponsored by Eli-Lilly.**
- 65. 2014-2016: Subinvestigator: A multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 study comparing solanezumab with placebo for 18 months in approximately 2100 patients with mild Alzheimer's Disease. Elli Lilly and Company. PI Douglas W Scharre.**
- 66. 2013-2016:Subinvestigator: A Randomized, double-blind, parallel-group, placebo controlled, fixed dose study of Lu AE58054 in patients with mild-moderate Alzheimer's Disease treated with donepezil; Study 1. Protocol 14861A. Sponsored by Lundbeck. PI Douglas W Scharre**

- 67. 2014-2016: Subinvestigator: A Randomized, Double Blind, Placebo-Controlled, Parellel-Group, 26-Week, Phase 3 Study of Two Doses of EVP-6124 or Placebo in subjects with Mild To Moderate Alzheimer’s Disease Currently or Previously Receiving an acetyl cholinesterase inhibitor medications. Forum Pharmaceuticals. PI Douglas W Scharre**
- 68. 2015-2016: Subinvestigator: A 26 Week Extension study of the Safety and Clinical Effects of EVP-6124 in subjects with Alzheimer’s Disease Currently or Previously Receiving an Acetyl Cholinesterase Inhibitor medication. Forum Pharmaceuticals. PI Douglas W Scharre**
- 69. 2014-2016: Subinvestigator: A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer’s Disease (The AMARANTH Study). D5010C00009. Astra Zeneca. PI Brendan Kelley.**
- 70. 2014-2016: Subinvestigator: A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy of MK-8931 (SCH 900931) in Subjects with Amnesic Mild Cognitive Impairment Due to Alzheimer’s Disease (Prodromal AD). MK-8931-8931(SCH 900931). Merck Sharp & Dohme, Corp., a subsidiary of Merck &C0., Inc. PI Douglas W Scharre**
- 71. 2014-2016: Subinvestigator: A Seamless Phase IIa/IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate the Efficacy and Safety of MK-7622 as an Adjunctive Therapy to Donepezil for Symptomatic Treatment in Subjects with Alzheimer’s Disease. MK-7622. Meck Sharp & Dohme, Corp., a subsidiary of Merck & C0., Inc. PI Douglas W Scharre**
- 72. 2014-2016:Subinvestigator: Protocol 14861B: An open-label extension study to evaluate the long-term safety and tolerability of Lu AE58054 as adjunctive treatment to donepezil in patients with mild-moderate Alzheimer’s Disease. 14861B WIRB Protocol #20132100. H. Lundbeck A/S. PI Douglas W Scharre**
- 73. 2015: Subinvestigator: Randomized, double-blind, paraller-group, placebo controlled, fixed dose study of Lu AE58054 in patients with mild-moderate Alzheimer’s disease treated with donepezil;study 1. H.Lundbeck A/S. PI Douglas W Scharre**
- 74. 2015: Subinvestigator: A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Efficacy and Safety Trial of MK-8931 with a long Term Double-Blind Extension in Subjects with Mild to Moderate Alzheimer’s Disease. Merck. PI Douglas W Scharre**
- 75. 2015: Subinvestigator: A phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer’s Disease. 221AD302. Biogen. PI Douglas W Scharre**

- 76. 2016: Subinvestigator: A phase 2b, double-blind, randomized, placebo-controlled study of RVT-101 in subjects with dementia with Lewy bodies(DLB). RVT-101-2001. Axovant Sciences, Ltd. PI Brendan Kelley.**
- 77. 2016: Subinvestigator: A phase 2b, double-blind, randomized, placebo-controlled cross over study of Nelotanserrin versus placebo in Lewy body dementia (LBD) subjects experiencing visual hallucinations (VH). RVT-102-2001. Axovant Sciences, Ltd. PI. Brendan Kelley.**
- 78. 2016: Subinvestigator: A phase 2, double-blind, randomized, placebo-controlled study of Nelotanserrin versus placebo in patients with Lewy body dementia (LBD) experiencing REM sleep behavior disorder (RBD). RVT-102-2002. Axovant Sciences, Ltd. PI. Brendan Kelley.**
- 79. 2016: Subinvestigator: A phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of AVP-786(deuterated (d6)-dextromethorphan hydrobromide (d6-DM)/quinidine sulfate(Q) for the treatment of agitation in patients with dementia of the Alzheimer's type. 15 –AVP-786-301. Avanir Pharmaceuticals. PI Douglas W Scharre.**
- 80. 2016: Subinvestigator: A phase 3 Multicenter, Long term, Extension Study of the Safety and Efficacy of AVP-786 (deuterated (d6) dextromethorphan hydrobromide (d6-DM)/quinidine sulfate for the treatment of Agitation in patients with Dementia of the Alzheimer's Type. Avanir Pharmaceuticals. PI Douglas W Scharre.**
- 81. 2016: Subinvestigator: Protocol#2014H0039 Validity of the electronic Self-Administered Gerocognitive Examination. (ESAGE).**
- 82. 2017: Subinvestigator:Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials (RAmP). 18F-AV-45-A25. Avid Pharmaceuticals. PI Douglas W Scharre.**
- 83. 2016: Subinvestigator: A Long Term Extension of the Safety and Tolerability of RVT-101 in Subjects with Dementia with Lewy Bodies(DLB). RVT-101-2002. Sponsor Axovant. PI. Brendan Kelley.**
- 84. 2016: Subinvestigator: An open-label study of nelotanserine in patients with Lewy body Dementia who have frequent visual hallucinations or REM sleep behaviors. RVT-102-2003. Axovant. PI. Brendan Kelley, M.D.**
- 85. 2017: Subinvestigator: A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia (The DAYBREAK Study). 18D-MC-AZET. Eli Lilly and Company. PI Douglas W Scharre.**
- 86. 2017:Subinvestigator: Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Ranging Study of Piromelatine in Patients with Mild Dementia Due to Alzheimer's Disease. NEUP11-AD2. Neurim. PI Douglas W Scharre.**

- 87. 2017: Subinvestigator: Alzheimer’s Disease Neuroimaging Initiative-3. ADNI-3. ATRI. F. Hoffmann-La Roche Ltd. PI Douglas W Scharre**
- 88. 2017: Subinvestigator: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study Of Crenezumab in Patients with Prodromal to Mild Alzheimer’s Disease. BN29553. PI Douglas Scharre.**
- 89. 2017: Co-investigator: Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3303560 in Patients with Mild Cognitive Impairment due to Alzheimer’s Disease or Mild to Moderate Alzheimer’s Disease. 18G-MC-LMDD. Eli Lilly and Company. PI Douglas Scharre.**
- 90. 2017: PI: A phase 2, double-blind, randomized, placebo-controlled study of Nelotanserin versus placebo in patients with Lewy body dementia (LBD) experiencing REM sleep behavior disorder (RBD). RVT-102-2002. Axovant Sciences, Ltd.**
- 91. 2017:PI:A phase 2, double-blind, randomized, placebo-controlled crossover study evaluating the effect of RVT-101 on gait and balance in subjects with Alzheimer’s Disease, Dementia with Lewy Bodies, or Parkinson’s Disease Dementia. RVT-101-2003.**
- 92. 2017:PI: An open-label study of nelotanserin in patients with Lewy body Dementia who have frequent visual hallucinations or REM sleep behaviors. RVT-102-2003. Axovant.**
- 93. 2017: PI: A phase 2, double-blind, randomized, placebo-controlled cross over study of Nelotanserin versus placebo in Lewy body dementia (LBD) subjects experiencing visual hallucinations (VH). RVT-102-2001. Axovant Sciences, Ltd.**
- 94. 2017:PI: A Long Term Extension of the Safety and Tolerability of RVT-101 in Subjects with Dementia with Lewy Bodies(DLB). RVT-101-2002. Sponsor Axovant. Amendment. Related Protocol: 2016W0140**

PEER REVIEW COMMITEES

Archives of Physical Medicine and Rehabilitation

American Journal of Obstetrics and Gynecology

Expert reviewer of the American Academy of Neurology (AAN) guideline protocol, “Pharmacologic Treatment of Migraine Headache in Children”. 6/2015

Expert reviewer OSUWMC Neuroscience program: Chronic Brain Injury, Discovery Theme Initiative, Pilot Award Review Criteria. 2/16.

American Academy of Neurology, Seminar Director, 4/ 2016.

Editorial Board member Journal of Memory Disorder and Rehabilitation, 2016-2017.

Alzheimer's, Dementia and Cognitive Neurology, 12/2016.

RESEARCH GRANTS SUBMISSION(not funded)

- **“ A randomized, multicenter, double-blind, parallel group, placebo-controlled study investigating the efficacy of Memantine plus Rivastigmine in patients with mild to moderate dementia of the Alzheimer's type”. Submitted to Novartis Pharmaceutical Corporation 7/04 PI.**
- **“Expression of APOE genotype polymorphisms in human brain”. PI Submitted 12/15/04 at The Ohio State University Office of Research College of Medicine & Public Health.**
- **“Early Diagnosis and Detection of Alzheimer's from EEGs” Submitted 2/1/05 NIH. CoPI.**
- **“Regulatory polymorphisms in candidate genes” Submitted at the American Health Assistance Foundation 10/13/06 Co PI. PI Wolfgang Sadee, OSU Pharmacology.**
- **“Efficacy of Shunt in Normal Pressure Hydrocephalus”: A Randomized Crossover Study. CoPI. Principal Investigator: Dr. Daniele Rigamonti, OSU PI Dr John McGregor. OSU IRB approval 1/30/13.**
- **“Attention Deficit Hyperactivity Disorder in Childhood: towards an improved recognition and therapeutic management. Submitted 6/15/17 at the Ministry of Development, Greece. Participation as scientific consultant with expertise in cognitive disorders.**

RESEARCH PROJECTS (Not funded research)

**1. “Prediction and Early Diagnosis of Alzheimer's Disease from EEG and MRI scans” IRB was approved October 11, 2004
Protocol No.: 2004H0205. Co PI in collaboration with the department of biomedical engineering, Dr Hojatt Adeli, OSU.**

2. **“Gene expression in human brain in patients with Alzheimer’s disease”. PI. In collaboration with the department of Pharmacology, Dr Wolfgang Sadee, OSU IRB was approved July 25, 2005. Protocol No.: 2005H0134**
3. **AFAR-OA student Alex Larson: Mentorship of a research project successfully completed: “A survival analysis of Alzheimer’s disease patients treated with antientia medications”. Data from The Buckey Brain Bank” Summer 2005-AFAR paper submitted 10/05**
4. **AFAR-OA student Kay Ritsie: Research Mentorship: Identification of clinical phenotypes on patients with Alzheimer’s disease and correlation with APOE phenotype analysis in brain tissue, Buckey Brain Bank data, successfully completed. Summer 2006.**
5. **“The use of Positron Emission Tomography for the early diagnosis of Mild Cognitive Impairment and Alzheimer’s Disease”. OSU Protocol No 2007E0295. Approved 4/25/07 in collaboration with Department of Radiology Dr Pozderac and Dr Sarikaya.**
6. **“Investigation of Selection bias in Neuroleptic Trials in Alzheimer’s” Protocol # 2007H0075 CoPI. PI David Beversdorf, Neurology. CoPI Douglas Scharre, Neurology approved 6/11/07.**
7. **“A multi-dimensional Creative Program for Mild Cognitive Impairment” OSU IRB protocol # 2011H0258. PI Christine Charyton, Psychology. CoPI Douglas Scharre, Neurology.**

TEACHING

1. **“Primary Degenerative Dementias: Resident Lecture, OSU Department of Neurology, November 2004.**
2. **“APOE and Alzheimer’s disease” A 10 year update. OSU Department of Neurology, Grand Rounds 2/25/05.**
3. **“Behavioral Neurology”. Resident Lecture. OSU Department of Neurology, 2/22/05.**
4. **Alzheimer’s Disease: An update in management” Department of Internal medicine, Residency Lecture. 8/2/05.**
5. **“Dementia”. Third year Medical student’s Neuroscience clerkship. OSU Department of Neurology, 3/15/06.**
6. **MED1 small group assorted cases. 3/10/06.**
7. **Resident’s journal club, attending leader discussion. Department of Neurology. OSU. 5/11/06.**

8. **The non Alzheimer's Dementias" OSU Department of Neurology, resident lecture series, 8/30/06.**
9. **MED1 small group assorted cases. 5/9/07.**
10. **"Dementia". M3 Neuroscience clerkship. OSU Department of Neurology, 5/9/07.**
11. **"Dementia". M3 Neuroscience clerkship. OSU Department of Neurology, 2/15/08.**
12. **Small group M1 Capstone facilitator case studies for the Independent Study Program, 4/4/08.**
13. **"Dementia". M3 Neuroscience clerkship. OSU Department of Neurology, 4/12/08.**
14. **"Dementia". M3 Neuroscience clerkship. OSU Department of Neurology, 6/26/08.**
15. **Grand Round Talk, "Prion Diseases". OSU Neurology. 1/6/09.**
16. **"Dementia". M3 Neuroscience clerkship. OSU Department of Neurology, 2/25/09.**
17. **"Dementia". M3 Neuroscience clerkship. OSU Department of Neurology, 4/22/09.**
18. **"Dementia". M3 Neuroscience clerkship. OSU Department of Neurology, 6/24/09.**
19. **"Prion Diseases" OSU Neurology, Resident's Lecture, 10/28/09.**
20. **"Dementia, overview". M3 Neuroscience clerkship. OSU Department of Neurology, 2/24/10.**
21. **"Dementia, overview". M3 Neuroscience clerkship. OSU Department of Neurology, 4/21/10.**
22. **Small Group M1 Assorted cases, 5/6/10.**
23. **Small Group M1 Assorted cases, 5/18/10.**
24. **"Dementia, overview". M3 Neuroscience clerkship. OSU Department of Neurology, 6/23/10.**
25. **"Alzheimer' Disease" Resident's Lecture, 10/15/10.**
26. **"Lewy Body Dementia" Resident's Lecture, 10/22/10.**
27. **"Dementia" M3 Neuroscience clerkship. OSU Department of Neurology, 10/27/10.**
28. **"Dementia" M3 Neuroscience clerkship. OSU Department of Neurology, 12/1/10.**
29. **"Dementia" M3 Neuroscience clerkship. OSU Department of Neurology, 2/23/11.**

30. "Dementia" M3 Neuroscience clerkship. OSU Department of Neurology, 4/20/11.
31. "Dementia" M3 Neuroscience clerkship. OSU Department of Neurology, 6/8/11.
32. "Dementia" M3 Neuroscience clerkship. OSU Department of Neurology, 10/19/11.
33. "Prion diseases" Resident's Lecture, OSU Department of Neurology, 11/21/11.
34. Invited Speaker Combined Neurology/Neurosurgery Grand Rounds, OSU, "Normal Pressure Hydrocephalus, An Overview". 12/1/11.
35. "Dementia" M3 Neuroscience clerkship. OSU Department of Neurology, 2/21/12.
36. "Dementia" M3 Neuroscience clerkship. OSU Department of Neurology, 5/2/12.
37. Small Group M1 Neuroscience course assorted cases, 5/10/12.
38. "Dementia" M3 Neuroscience clerkship. OSU Department of Neurology, 6/13/12.
39. "Dementia" M3 Neuroscience clerkship. OSU Department of Neurology, 8/22/12.
40. "Alzheimer's Disease an update". Resident's lecture. OSU Department of Neurology 10/10/12.
41. "Dementia, an update" M3 Neuroscience clerkship. OSU Department of Neurology, 10/10/12.
42. "Subcortical Dementias". Resident's Lecture series. OSU Department of Neurology 10/24/12.
43. "Parkinsonian Dementias". Resident's Lecture series. OSU Department of Neurology 10/29/12.
44. "Dementia, an update" M3 Neuroscience clerkship. OSU Department of Neurology, 2/20/13.
45. "The Cortical Syndromes" M1 Articulate module presentation, 2/25/13. The Ohio State University, College of Medicine.
 - a. <http://vitals.osumc.edu/articulate/2559/player.html>
46. "Dementia, an update" M3 Neuroscience clerkship. OSU Department of Neurology, 5/1/13.
47. "Dementia, an update" M3 Neuroscience clerkship. OSU Department of Neurology, 5/15/13.

48. **“Dementia, an update” M3 Neuroscience clerkship. OSU Department of Neurology, 8/21/13.**
49. **“Prion Diseases” Resident Lecture, OSU Neurology. 10/30/13.**
50. **“Dementia, an update” M3 Neuroscience clerkship. OSU Department of Neurology, 12/11/13.**
51. **“The Other Cortical Syndromes”, articulate course in LSI curriculum, on line module. The Ohio State University, module in neurological disorders, 2/25/14 OSU College of Medicine.**
52. **“Dementia, an update” M3 Neuroscience clerkship. OSU Department of Neurology, 4/2/14.**
53. **“Dementia, an update” M3 Neuroscience clerkship. OSU Department of Neurology, 5/7/14.**
54. **“Alzheimer’s Disease an update in diagnosis and management”. Resident’s lecture series. OSU Department of Neurology 4/8/15.**
55. **NeuroPI: Falls Refresh module. Donald J. Iverson, MD, FAAN, NeuroPI Editor
Author: Maria Kataki MD, PhD, Germaine Odenheimer, MD, FAAN. American Board of Psychiatry and Neurology Core Competencies. 09/2015.**
56. **“Lewy Body Dementia”. Resident’s lecture series OSU Department of Neurology 4/16/15.**
57. **“The Spectrum of Prion Diseases”. Resident’s lecture series. OSU Department of Neurology 10/22/15.**
58. **Management of Behavioral Disturbances in Dementia. AAN Breakfast Seminar Director-Introduction. AAN 4/20/16.**
59. **Management of Agitation and Psychosis in Dementia. Presentation AAN Breakfast Seminar Management of Behavioral Disturbances in Dementia. AAN 4/20/16.**
60. **“Alzheimer’s Disease an update in diagnosis and management”. Resident’s lecture series. OSU Department of Neurology 5/10/17.**

PUBLICATIONS

SYLLABI

- **Maria Katakis: Author: CNS Pathophysiology module, Independent Study Program, The Ohio State University, 2007. College of Medicine.**
- **Maria Katakis: Author: CNS Pathophysiology module, Independent Study Program, The Ohio State University, 2008. College of Medicine (update).**
- **Maria Katakis: Author: CNS Pathophysiology module, Independent Study Program, The Ohio State University, 2009. College of Medicine (update).**
- ***Maria Katakis: CNS Pathophysiology Module 2011 syllabus (update). The Independent Study Program. The Ohio State University, College of Medicine.***
- ***Maria Katakis: The Other Cortical Syndromes, articulate course 2013 in LSI curriculum. The Ohio State University, College of Medicine. 2/25/13.***
<http://vitals.osumc.edu/articulate/2559/player.html>
- ***Maria Katakis: The Other Cortical Syndromes, articulate course 2013 in LSI curriculum. The Ohio State University, College of Medicine. 2/24/14.***
- **Management of Behavioral Disturbances in Dementia. AAN Breakfast Seminar Director-syllabi on line. AAN 4/20/16.**
- **NeuroPI: Falls Refresh module. NeuroPI Editor Author: *Maria Katakis MD, PhD, Germaine Odenheimer, MD, FAAN, Donald J. Iverson, MD, FAAN . American Board of Psychiatry and Neurology Core Competencies 9/2015***
- **Management of Behavioral Disturbances in Dementia. AAN Breakfast Seminar Director- on line syllabi AAN 4/20/2016, www.aaan.com/tool/C171.**
- **Management of Agitation and Psychosis in Dementia. Presentation AAN Breakfast Seminar Management of Behavioral Disturbances in Dementia. AAN 4/20/16. www.aan.com/tools/C171.**

REFERRED JOURNAL ARTICLES

1. **G. Paraskevas, *M.Katakis*, N. Triantafilou, C. Sfagos, C.Papageorgiou, “Brain Stem Encephalitis: case report,” (Journal of the Greek Neurological Association) *Neurologia* 2: 5-9, 1993.**
2. ***M. Katakis*, J. Winikates, J. Kirkpatrick, R. Doody, “A Longitudinal study of Aphasia in Creutzfeldt-Jakob Disease,” *Neuropsychiatry, Neuropsychology, and Behavioral Neurology*, 9:284-287, 1996.**

3. JW Wheless, LJ Willmore, JI Breier, *M Katakis*, JR Smith, DW King, KJ Meador, GL Clifton, J Baumgartner, AB Thomas, JEC Constantinou, AC Papanicolaou, “A Comparison of Magnetoencephalography, MRI, and V-EEG in Patients Evaluated for Epilepsy Surgery”. *Epilepsia*, 40(7) 931-941,1999.
4. Papanicolaou A, Simos P, Zouridakis G, *Katakis M* “The mapping of receptive language cortex using Magnetoencephalography” *Egkephalos*, 36(4): 221-235, 1999.
5. Zouridakis G. and *Katakis M*. “Functional Neurosurgery: Overview and Application Examples” In *Research Advances in Biomedical Engineering*, GRN, 2001
6. *Katakis M*, Hill A, Schulz PE. West Nile Virus Encephalitis. Case of the month: Case 65 (2002), <http://www.bcm.tmc.edu/neurol/case.html>. Department of Neurology, Baylor College of Medicine
7. *Katakis M*. Coccidioides meningoencephalitis, Case 70 (2003), <http://www.bcm.tmc.edu/neurol/case.html>. Department of Neurology, Baylor College of Medicine.
8. R. S. Doody, J. K. Dunn, E. Huang, S. Azher, *M. Katakis*: “A Method for Estimating Duration of Illness In Alzheimer’s Disease”. *Dementia and Geriatric cognitive disorders*, Vol. 17, No. 1-2, pp 1 - 4 , 2004.
9. Houda Alachkar, Audrey Papp, *Maria Katakis*, Douglas W. Scharre, and Wolfgang Sadee Title: “Allelic mRNA expression of sortilin-1 (SORL1) mRNA in Alzheimer’s autopsy brain tissues” *Neuroscience Letters* Ms. No.: NSL-08-1182R1. 5-NOV-2008 DOI information: 10.1016/j.neulet.2008.10.034
10. Scharre, Douglas W.; Chang, Shu-Ing; Murden Robert A; Lamb, James ; Beversdorf, David Q; *Katakis, Maria*; Nagaraja, Haikady N; Bornstein, Robert A. “Self-administered Gerocognitive Examination (SAGE): A Brief Cognitive Assessment Instrument for Mild Cognitive Impairment (MCI) and Early Dementia. *Alzheimer Disease & Associative Disorders: January/March 2010-Volume 24 – Issue 1 – pp 64 – 71* doi: 10.1097/WAD.obo13e3181b03277.
11. Julia K Pinsonneault, Dawn Han, *Maria Katakis*, Alessandro Bertolino, Anil Malhotra, Howard Gu and Wolfgang Sadee. Manuscript NP-10-0993R, “Dopamine transported gene variant affecting expression in human brain is associated with bipolar disorder” *EUROPSYCHOPHARMACOLOGY*. Vol. 36, no. 8. (Jul 2011): 1644-1655. (7.99)
12. NeuroPI: Falls Refresh module. NeuroPI Editor Author: *Maria Katakis MD, PhD*, Germaine Odenheimer, MD, FAAN, Donald J. Iverson, MD, FAAN . American Board of Psychiatry and Neurology Core Competencies 9/2015.

13. Douglas W. Scharre, MD; Shu-Ing Chang, PharmD; Haikady Nagaraja, PhD; Ariane Park, MD, MPH; Anahita Adeli, MD; Punit Agrawal, DO; Anne Kloos, PT, PhD; Deb Kegelmeyer, DPT, MS; Shannon Linder, CNP; Nora Fritz, DPT, PhD; Sandra K. Kostyk, MD, PhD; *Maria Katakai, MD, PhD*. “Paired studies comparing Lewy body dementia with Alzheimer’s and Parkinson’s Disease”. DOI: 10.3233/JAD-160384. Journal: [Journal of Alzheimer's Disease](#), vol. 54, no. 3, pp. 995-1004, 2016
14. Management of Behavioral Disturbances in Dementia. *Maria Katakai*. AAN Breakfast Seminar Director- on line syllabi AAN 4/20/2016, www.aan.com/tool/C171.
15. Management of Agitation and Psychosis in Dementia. Presentation AAN Breakfast Seminar Management of Behavioral Disturbances in Dementia. *Maria Katakai*. AAN 4/20/16. On line chapter on syllabi Management of Behavioral Disturbances in Dementia. www.aan.com/tools/C171.
16. Nora Fritz, PhD, DPT, GCS; Anne Kloos, PT, PhD, NCS; MPH; *Maria Katakai, MD, PhD*; Anahita, Scharre, MD; Sandra Kostyk, MD, PhD: Motor Performance Differentiates Individuals with Lewy Body Dementia, Parkinson's and Alzheimer's Disease. [Gait & Posture Volume 50](#), October 2016, Pages 1–7
17. Gene expression profiling of brain samples from patients with Lewy Body dementia. Maciej Pietrzak, Audrey Papp, Amanda Curtis, Samuel K Handelman, *Maria Katakai*, Douglas Scharre, Grzegorz Rempala and Wolfgang Sadee. [Biochemical and Biophysical Research Communications Volume 479, Issue 4](#), 28 October 2016, Pages 875–880

BOOK CHAPTERS

1. *M. Katakai, H. Schmolck, P. Schulz*: “Behavioral Neurology” Book chapter in *Neurology Secrets*, Rolak 4th edition, 2004.
2. *Maria Katakai*: “Dementia”. Book Chapter for CNS Pathophysiology module for the independent study program, The Ohio State University, College of Medicine, 2/2007
3. *Maria Katakai*: “Dementia”. Book Chapter for CNS Pathophysiology module for the independent study program, The Ohio State University, College of Medicine 2/2008.
4. *Maria Katakai*: “Diagnosis of Mild Cognitive Impairment and Dementia”. Book Chapter in “Long-Term Management of Dementia”, Scharre edition 2010 [9780849338533].
5. *Maria Katakai*: “Intracerebral hemorrhage”. Book chapter CNS Pathophysiology Module 2011. The Independent Study Program. The Ohio State University, College of Medicine 2011.

6. M Racke and *Maria Kataki*: “Disorders of the Myelin”. Book chapter CNS Pathophysiology Module 2011. The Independent Study Program. The Ohio State University, College of Medicine 2011.
7. *Maria Kataki*: “Disorders of Higher Cortical Function”. Book Chapter for CNS Pathophysiology module for the independent study program, The Ohio State University, College of Medicine 2011.
8. *Maria Kataki*: The Other Cortical Syndromes, articulate course in LSI curriculum. The Ohio State University, module in neurological disorders, 2013 College of Medicine.
9. *Maria Kataki*: The Other Cortical Syndromes, articulate course in LSI curriculum. The Ohio State University, module in neurological disorders, 2014 College of Medicine.

I have been an investigator at the ADNI study for a number of years. This study group has produced 241+ papers (2004-2014) from collaborative research as part of the ADNI study group. I have contributed with subject recruitment, data collection, research evaluations and ongoing participation at the ADNI study group. During the years 2015-2016 the ADNI study group has published 120+ papers.

ABSTRACTS

1. "Self-Administered Gerocognitive Examination (SAGE): Validity and Reliability of a Brief Cognitive Screening Instrument for Mild Cognitive Impairment (MCI) and Early Dementia". Douglas Scharre, Chang Shu-Ing, David Beversdorf, *Maria Kataki*, Haikady Nagaraja, and Robert Bornstein. Poster AAN 60th annual meeting 2008.
2. “Self Administered test to screen for Mild Cognitive Impairment and Early Dementia”: D. W. Scharre, S. Chang, R. Murden, J. Lamb, D. Q. Beversdorf, *M. Kataki*, H. N. Nagaraja, R. Bornstein. Presidential Poster AGS 2008. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*, Vol. 4, Issue 4, T270
Published in issue: July 2008
3. Self-Administered Gerocognitive Examination (SAGE): Validity of a Brief Cognitive Screening Instrument for Detection of Early Dementia. International

Neuropsychological Society (INS) 37th Annual Meeting 2/09. D.W. Scharre, S. Chang, D. Beversdorf, *M. Katakai*, H. Nagaraja, R. Bornstein.

4. "Self Administered Gerocognitive Examination (SAGE) Score Changes over Time in Worried Well, Mild Cognitive Impairment (MCI), and Dementia Converter Patients," 21st Annual Meeting of the American Neuropsychiatric Association. March 17 -2010 Scharre DW, Chang S-I, *Katakai M*, and Nagaraja HN.
5. Self Administered Gerocognitive Examination (SAGE) and Mini–Mental State Examination (MMSE) Score Changes over Time in Worried Well, Mild Cognitive Impairment (MCI) and Dementia Converter Patients" American Academy of Neurology 62nd Annual Meeting, April 13, 2010 Toronto, Ontario, Canada. D. W. Scharre, S. Chang, *M. Katakai*, H. N. Nagaraja PO2.053.
6. Self Administered Gerocognitive Examination (SAGE) and Mini–Mental State Examination (MMSE) Score Changes over Time in Worried Well, Mild Cognitive Impairment (MCI) and Dementia Converters and Alzheimer’s Disease Patients" ICAD Alzheimer’s Association Conference International Conference. D. W. Scharre, S. Chang, N. C. Wheeler, *M. Katakai*, H. N. Nagaraja. Poster presentation # A 1641. Honolulu, Hawaii 7/12/2010. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*, Vol. 6, Issue 4, S369–S370
Published in issue: July 2010
7. “Differences in the Cognitive Profiles of Parkinsonian Dementia Syndromes and Alzheimer’s Disease Scharre DW, Chang SI, *Katakai M*, Agrawal P, Park A, Kostyk S, Davis R, Kovesci R, Nagaraja HN. Poster presentation, American Medical Directors Association meeting in San Antonio, March 2012.
8. “Memory Profiles Differ between Parkinsonian Dementia Syndromes and Alzheimer’s Disease”. Scharre DW, Chang SI, *Katakai M*, Agrawal P, Park A, Kostyk S, Nagaraja HN. Poster presentation ID#30765 Alzheimer’s Association International Conference (AAIC) 2012 Vancouver, British Columbia, Canada, July 14-19, 2012.
9. “Distinguishing Parkinsonian Dementia Syndromes from Alzheimer’s Disease: Behavioral and Cognitive Characteristics Using SAGE” poster presentation at the American Academy of Neurology 65th Annual Meeting, March 16 to March 23, 2013. San Diego Convention Center, San Diego, CA. Scharre WD, Cang SI, Nagaraja HN, Agrawal P, *Katakai M*, Linder S, Park A.
10. "Multiplexed RNA amplicon sequencing reveals altered gene expression and functional regulatory variants in dementia with Lewy bodies," Poster #430, 11/11/13 San Diego, CA Neuroscience 2013. Control/Tracking Number: 2013-S-12302-SfN.:
*R. Maschrenchas R., M. Smith, A. C. Papp, D. W. Scharre, *M. Katakai*, W. Sadee.

11. Paired Comparison Study Distinguishing Parkinsonian Dementia Syndromes from Parkinson's Disease". Poster presentation #2360 American Academy of Neurology 66th Annual Meeting 4/30/2014: Douglas Scharre, Shu-Ing Chang; Haikady Nagaraja; Ariane Park; Punit Agrawal, Anahita Adeli, Shannon Linder; Anne Kloos, Deborah Kegelmeyer, Nora Fritz, *Maria Katak*i.

12. "Motor and Cognitive Profiles Differ between Lewy Body Dementia and Parkinson's Disease in a Paired Comparison Study". Poster presentation #44166. ICAD. Douglas W. Scharre, Shu-Ing Chang; Haikady Nagaraja; Ariane Park; Punit Agrawal, Anahita Adeli, Shannon Linder; Anne Kloos, Deborah Kegelmeyer, Nora Fritz, *Maria Katak*i, Sandra Kostyk. 7/15/14 Copenhagen, Denmark. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*, Vol. 10, Issue 4, P677
Published in issue: July 2014

13. "Comparison of gait and mobility measures in Dementia with Lewy Bodies, Parkinson's Disease with Dementia, Alzheimer's Disease, and Parkinson's Disease". DA Kegelmeyer, AD Kloos, NE Fritz , SI Chang, A Park , P Agrawal, A Adeli , S Linder , *M Katak*i , DW Scharre , SK Kostyk. Parkinson's Study Group meeting in September 2014 in St. Louis. Abstract in the journal *Movement Disorders*.

14. "Longitudinal Changes in Self-Administered Gerocognitive Examination (SAGE) Scores for Subjective Cognitive Impairment (SCI), Mild Cognitive Impairment (MCI), Dementia Converters, and Alzheimer's Disease (AD) Patients. Poster Presentation P4.088 AAN 67th meeting 4/22/2015. Douglas Scharre, Shu-Ing Chang, Haikady Nagaraja, *Maria Katak*i, Natalie Wheeler, Anahita Adeli.

15. "Longitudinal Changes in Self-Administered Gerocognitive Examination (SAGE) and Mini-Mental State Examination (MMSE) Scores for Subjective Cognitive Impairment (SCI), Mild Cognitive Impairment (MCI), Dementia Converters, and Alzheimer's Disease (AD) Patients". Poster Presentation AAIC 7/20/15. Douglas Scharre, Shu-Ing Chang, Haikady Nagaraja, *Maria Katak*i, Natalie Wheeler, Anahita Adeli. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*, Vol. 11, Issue 7, P570. Published in issue: July 2015

16. "Gene expression profiling of anterior cingulate cortex from subjects with Lewy body dementia". Poster Presentation SFN annual meeting. October 19, 2015 M. Pietrza, A. Papp, A. Curtis, M. Kataki, D. Scharre, G. Rempala, W. Sadee.

17. Digital Self Administered Examination eSAGE. Abstract ID a10039 in *Alzheimer's and Dementia conference proceedings*. AAIC July 28 2016, Toronto, CA. Oral presentation. D. Scharre, S Chang, H Nagaraja, N Vrettos, *M Katak*i.

18. Digital Translated Self-Administered Gerocognitive Examination (eSAGE): Relationship to Clinical Assessments. *Alzheimer's and Dementia conference proceedings*. AAIC July 16 2017, London, England. Poster presentation. Scharre DW, Chang S-I, Nagaraja HN, Vrettos N, Kataki M.

PUBLISHED ABSTRACTS NOT OTHERWISE PUBLISHED IN ARTICLE FORM

19. "Antiphospholipid antibodies syndrome, Neurological complications. Presentation of four cases". T. Zambelis, *M Katakis*, C. Boumbourakis, E. Andreadou, L. Besmertis, C. Papageorgiou. Abstracts of 14th Annual Conference of Greek Neurological Association. 11/95 (Abstract in Neurologia).
20. "Event Related Evoked Potentials in patients with Dementia". N. Triantafyllou, *M. Katakis*, K. Papageorgiou, Abstracts of 14th Conference of Greek Neurological Association. 11/95 (Abstract in Neurologia).
21. "SPECT study in Alzheimer's Disease and correlations with disease severity and cognitive performance". *M.Katakis*, N. Sifakis, A. Kolintou, I. Zalonis, P. Sgouropoulos, P. Kostamis, C. Papageorgiou. Abstracts of 14th Annual Conference of Greek Neurological Association. 11/95 (Abstract in "Neurologia").
22. "Semiquantitative analysis of SPECT with ROIs in Alzheimer's disease patients." N. Sifakis, *M. Katakis*, P. Sgouropoulos, P. Kostamis, A. Kolintou, C. Papageorgiou., Abstracts of Fifth Greek Annual Conference on Nuclear Medicine, Patras, Greece, March 1996.
23. "Contributions of SPECT in the assessment of Alzheimer's disease." *M. Katakis*, P. Gourtzelidis, N. Sifakis, A. Kolintou, I. Zalonis, P. Sgouropoulos, P. Kostamis, and C. Papageorgiou. Abstracts of the Fifteenth Annual Conference on Biomedical Engineering Research in Houston, p. 169, 1997.
24. "SPECT study in Dementia." *M. Katakis*, P. Gourtzelidis, N. Sifakis, A. Kolintou, I. Zalonis, P. Sgouropoulos, S. Perisinaki, P. Kostamis, and C. Papageorgiou. Abstracts of the twentieth Third Annual Hellenic Conference on Medicine in Athens 1997, p. 19.
25. "Stereotactic Radiosurgery of Angiographically Occult Vascular Malformations". *M. Katakis*, N. Hashimoto, O. Zeck, W. Gormley. Abstracts of sixteen Annual Conference on Biomedical Engineering Research in Houston, 1997, p. 137.
26. "The Presence of APOε4 does not Influence Rate of Decline in Alzheimer's Disease". *M. Katakis*, R.S. Doody, J. Y. Liao, J. Sims. 6th International Conference on Alzheimer's disease and Related Disorders. Amsterdam Rai 18-23 July 1998. Neurobiology of aging 19:4S, S 137, 1998.
27. "SPECT findings in Alzheimer's Disease and correlation with disease severity" poster presentation in the 9th International Conference on Alzheimer's Disease and Related Disorders, Philadelphia, Pennsylvania, USA, July 17-22, 2004. *M Katakis*, P

Sgouropoulos, N Sifakis. Citation: NeuroBiology of Aging, Volume 25, Number S2 , July 2004, Page 95.

28. "Effect of Donepezil on left inferior frontal lobe activation during verbal fluency in MCI". A Narayanan, C. A White, N. Kim, M. E. Tivarus, A Hillier, P Schmalbrock, M Katak, D. Scharre, D. Beversdorf. Abstract presented in the AAN 2007.

LANGUAGES:

Greek, English, French

REFERENCES

Available upon request